| 14.05 07:01 | dpa-AFX: EQS-News: Biophytis announces the design of its phase 2 OBA clinical study in obesity (english) |
| 29.04 14:41 | dpa-AFX: EQS-News: Biophytis is deploying its partnership strategy in obesity (english) |
| 24.04 23:01 | dpa-AFX: EQS-News: Biophytis Announces Transfer of ADSs to OTC Market (english) |
| 19.04 07:02 | dpa-AFX: EQS-News: Biophytis announces ratio change under its American Depositary Receipt ("ADR") program (english) |
| 18.04 07:04 | dpa-AFX: EQS-News: Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity (english) |
| 08.04 23:03 | dpa-AFX: EQS-News: Biophytis announces its 2023 financial results and provides an update on its business activities (english) |
| 08.04 23:01 | dpa-AFX: EQS-News: Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) (english) |
| 04.04 23:01 | dpa-AFX: EQS-News: RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 (english) |
| 22.03 07:02 | dpa-AFX: EQS-News: Biophytis presented its phase 3 protocol in the treatment of sarcopenia (english) |
| 17.11 23:01 | dpa-AFX: EQS-News: Biophytis announces receipt of Nasdaq Notice (english) |
| 30.10 06:01 | dpa-AFX: EQS-News: Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil (english) |
| 27.10 23:01 | dpa-AFX: EQS-News: Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel (english) |
| 27.09 23:16 | dpa-AFX: EQS-News: Biophytis releases its half-yearly accounts as of 30 June 2023 and provides an update on its operations (english) |
| 25.09 07:08 | dpa-AFX: EQS-News: Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) (english) |
| 19.09 07:01 | dpa-AFX: EQS-News: Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19 (english) |
| 14.09 07:01 | dpa-AFX: EQS-News: Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer (english) |
| 11.09 07:01 | dpa-AFX: EQS-News: Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia (english) |
| 04.09 23:01 | dpa-AFX: EQS-News: Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York (english) |
| 16.08 07:01 | dpa-AFX: EQS-News: Biophytis announces next regulatory steps in Europe and the United States for its COVA project (english) |
| 08.08 07:01 | dpa-AFX: EQS-News: Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe (english) |
|
|
